摘要
原发免疫性血小板减少症(ITP)属自体免疫性病变,该病目前无根治方法,故治疗旨在止血、延缓疾病进展、预防复发、减少用药疗程、提高患者生活质量。为了更有效地治疗ITP患者,不少研究提出了联合用药的新策略。联合用药基于作用不同致病靶点,引发加性或协同效应,使得疾病完全缓解率及总有效率明显优于单药治疗,且复发率低、安全性高。此种治疗思维可以用于加强疾病初始治疗,进而预防疾病复发,减慢疾病进展。糖皮质激素、利妥昔单抗以及艾曲波帕分别针对疾病不同发病机制达到提升血小板的目的,因此本文对其分别联合其他药物治疗ITP的情况进行简述。
Primary immune thrombocytopenia(ITP)is an autoimmune disorder for which there is no definitive cure,and current treatment aims to achieve hemostasis,delay disease progression,prevent recurrence,shorten the duration of medication and improve patients’quality of life.In order to treat ITP patients more effectively,a number of studies have proposed a new strategy:drug combination treatment.The drug combination treatment,based on acting on different pathogenic targets to trigger additive or synergistic effects,results in significantly better rates of complete disease remission and overall effective rate than monotherapy,with lower relapse rates and a higher safety profile.Such a treatment approach can be used to enhance the initial treatment of the disease,thereby preventing relapse and slowing disease progression.Glucocorticoids,rituximab and eltrombopag can each target a different pathogenesis of the disease to increase platelet content,so this paper briefly reviews their respective combinations with other drugs for the treatmen t of ITP.
作者
胡星月
赵彤
张思源
乐丽霞
宋朋飞
李洁
HU Xingyue;ZHAO Tong;ZHANG Siyuan;LE Lixia;SONG Pengfei;LI Jie(Department of Hematology,Hongqi Hospital Affiliated to Mudanjiang Medical University,Heilongjiang,Mudanjiang 157000,China;Department of Radiology,Hongqi Hospital Affiliated to Mudanjiang Medical University,Heilongjiang,Mudanjiang 157000,China;Department of Rheumatology and Immunology,Hongqi Hospital Affiliated to Mudanjiang Medical University,Heilongjiang,Mudanjiang 157000,China)
出处
《中国医药科学》
2023年第14期45-48,85,共5页
China Medicine And Pharmacy
基金
黑龙江省牡丹江市应用技术研究与开发计划项目(YJSZX2022051)。
